Hengrui Pharma to present 64 oncology research studies at ESMO 2026

Hengrui Pharma is set to disclose data from 64 oncology research projects at the European Society for Medical Oncology (ESMO) 2026 congress. The presentation lineup includes three 'Proffered Paper' sessions and three 'Rapid Oral' slots, marking a significant presence for the company in the international oncology research community.

The findings span more than ten distinct areas within oncology and supportive care. A major portion of the data, comprising over ten individual studies, investigates HER2 and HER3-targeted antibody-drug conjugates (ADCs), which represent a central component of the company’s drug development pipeline.

This broad disclosure aims to provide further clarity on the clinical efficacy and safety profiles of the company's experimental portfolio. By securing multiple high-profile presentation slots, Hengrui Pharma intends to demonstrate its research capabilities to oncologists and industry stakeholders currently monitoring the development of targeted cancer therapies.